DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based biotech firm with a market capitalization of $13.24 million, revealed promising results from a recent pre-pivotal clinical trial for its ...

This study reinforces the significance of intensive glycaemic control and is a paradigm shift in managing the disease and its complications.

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

KeyBanc highlighted WST, GXIG, and STVN as the main beneficiaries following robust demand in the Continuous Glucose ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

A new error grid to assess the accuracy of glucose measurements could give continuous glucose monitor manufacturers and ...